Phase II and pharmacokinetic study of CPT-11 [irinotecan] and trastuzumab (RhuMab HER2, Herceptin) in advanced colo-rectal cancer with p185 HER 2 overexpression

Trial Profile

Phase II and pharmacokinetic study of CPT-11 [irinotecan] and trastuzumab (RhuMab HER2, Herceptin) in advanced colo-rectal cancer with p185 HER 2 overexpression

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2013

At a glance

  • Drugs Irinotecan (Primary) ; Trastuzumab (Primary)
  • Indications Colorectal cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 07 Feb 2013 Actual end date added as 1 Mar 2006 as reported by ClinicalTrials.gov record.
    • 11 Jan 2007 Status changed from in progress to completed
    • 15 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top